What happens when you stop taking Mounjaro?

Three things happen when you stop Mounjaro: appetite comes back over the following weeks, some of the weight returns over the following year, and digestion speeds back up. In the one trial that measured it, people who switched from tirzepatide to placebo regained 14% of their body weight in a year, while those who stayed on lost a further 5.5%.¹ None of it happens overnight, because tirzepatide (the medicine in Mounjaro) clears from the body gradually, and none of it is universal: how much weight returns, and how fast, varies widely.

Sources checked on 4 November 2026.

Stopping is the last chapter of the Wellgard guide to living well on Mounjaro; before deciding the medicine has stopped working, read why weight loss stalls.

How quickly does Mounjaro leave your system?

Tirzepatide has an elimination half-life of about five days,² so it is largely cleared about a month (five half-lives) after your last injection. The arithmetic: the last injection reaches its peak level 8 to 72 hours after you inject, and from there the level halves roughly every five days, to about a half at day five, a quarter at day ten, an eighth at day 15, a sixteenth at day 20 and around 3% at day 25.² The product information uses the same window from the other direction: it asks for the medicine to be stopped at least a month before a planned pregnancy because of its long half-life.² Effects are expected to fade over the same weeks as the level falls; no trial has timed the return of appetite day by day.

Why hunger comes back, and why it is not a willpower problem

Tirzepatide activates the receptors for two gut hormones, GLP-1 and GIP, which reduces appetite and helps you feel fuller for longer.³ When you stop, your body's own hunger-and-fullness system, which had been working against the weight loss all along, is unopposed again. This is not specific to Mounjaro. In a study of 50 adults who lost weight on a ten-week very-low-energy diet, leptin (a fullness hormone) was still lower and ghrelin (a hunger hormone) still higher a year later, and the participants still reported more hunger than before they lost the weight.⁴ Mounjaro overrides that response; stopping removes the override.

Will you regain the weight? What the trial data shows

Often, and usually partially. SURMOUNT-4 followed 670 adults who had lost an average of 20.9% of their starting weight over 36 weeks on tirzepatide, then randomised them to continue or switch to placebo for 52 weeks. Those who stayed on lost a further 5.5%; those who switched regained 14% of their week-36 weight and ended the trial 9.9% below their starting weight, so on average they gave back more than half of the loss.¹

The average hides wide variation: some people keep most of their loss, others regain most of it within months. In the one trial that tested it, exercise begun during treatment with an incretin medicine was followed by less regain a year after the medicine ended.⁵ A pooled analysis of eight trials found that extra support in the maintenance phase alone made little difference; its authors conclude that maintenance has to start during the weight-loss phase.⁶

Why am I still losing weight after stopping Mounjaro?

Some people keep losing for a short while after stopping. Because tirzepatide clears gradually over about a month,² some appetite-suppressing effect is still present in the weeks after your last dose, and your portion sizes and routines do not vanish the day you stop. The reversal shows up later, as both fade.

What about blood pressure, cholesterol and blood sugar?

If Mounjaro improved your blood pressure, cholesterol or blood sugar, those gains can partially reverse with regain: in real-world data, weight regain after stopping incretin medicines is associated with worsening cardiometabolic markers.⁵ This matters most if you take Mounjaro for type 2 diabetes, so speak to your prescriber before you stop, not after.

Should you taper off, or is stopping abruptly fine?

This is unsettled. The argument for tapering is that a sudden loss of appetite suppression could trigger a sharper rebound in hunger than a gradual reduction. It is plausible, but because tirzepatide leaves the body gradually over about a month however you stop,² there is no strong trial evidence that a formal taper reduces regain. Either way, tell your prescriber before stopping.

What side effects can happen after stopping?

As stomach emptying returns to normal, some people notice temporary bloating, wind or mild nausea, the reverse of the adjustment when starting. Appetite and food noise return over the following weeks, and some people report low energy or low mood. The medicine's product information lists no withdrawal syndrome or dependence.²

How many days or weeks that takes is not a figure the record gives. No published trial has timed the fading of gut side effects or the return of hunger day by day after a last dose. SURMOUNT-4, the one randomised withdrawal trial, measured body weight, waist, blood pressure, blood fats, blood sugar and physical-function questionnaires over the 52 weeks after the switch to placebo, not appetite, and counted gut side effects across the whole year, when they were less common in the placebo group than in those who continued.¹ A 2026 pooled analysis of six studies of stopping semaglutide or tirzepatide (8,993 adults) records the same direction: in the two trials that reported them, gut side effects were fewer after stopping, with no timescale given.¹² What the record supports is the clearance window above: the medicine's level falls by about half every five days and is largely gone within about a month.² How closely the slowing of the stomach and the brake on appetite follow that curve has not been measured. The NHS says to talk to your doctor if you want to stop, and not to stop suddenly; your doctor may suggest reducing the dose gradually.³

What happens to muscle after stopping?

Stopping the medicine does not itself cause muscle loss; the risk is indirect, and it runs both ways. In the SURMOUNT-1 body-composition substudy, about a quarter of the weight lost on tirzepatide was lean mass and three-quarters was fat, the same proportions as on placebo.⁷ Weight regained without resistance training or enough protein skews towards fat.⁵ Together, that can mean a worse muscle-to-fat ratio at the same number on the scale. Resistance training and protein protect muscle through any weight change: in six trials in older adults losing weight by diet, resistance training three times a week prevented almost all of the lean mass loss.⁸ Protein needs do not fall when the medicine stops.

How to protect your results

• Keep up resistance training, two to three sessions a week, progressing it; it is the best-evidenced lever for keeping muscle.⁸
• Keep protein intake up. The diet-trial range for people losing or maintaining weight is 1.2 to 1.6 g of protein per kilogram of body weight a day, in meals of at least 25 to 30 g;⁹ ask your GP first if you have kidney disease.
• Keep fibre at 30 g a day, the UK government guideline.¹⁰ Fibre blunts the appetite that is coming back.
• Keep the habits, not just the willpower: the meal times, portion sizes and three-meals floor you built on Mounjaro.
• Stay active generally. Exercise during treatment was followed by less regain afterwards in the one trial that tested it.⁵
• Weigh in weekly, so a small drift can be acted on early.

How to keep the weight off after stopping Mounjaro

The common suggestions, berberine, a keto diet, fasting and the supplements marketed as GLP-1 boosters, are offered as replacements, and none reproduces the medicine's hormone signalling. Berberine has an evidence base of its own, but it is a glucose one: across 37 randomised trials in 3,048 people with type 2 diabetes, it lowered HbA1c by about 0.6 percentage points,¹¹ against the 20.9% weight loss on tirzepatide over 36 weeks.¹ It interacts with several common medicines; ask a pharmacist first. What the maintenance research supports is the list above, started while you were still losing.^{5, 6} If regain is faster than you can manage, a maintenance dose or going back on is a prescriber conversation, not a defeat.

Is there such a thing as a Mounjaro maintenance dose?

For some people, yes. Staying on a lower dose long-term, rather than stopping altogether, is part of the conversation with a prescriber, given how often regain follows stopping completely.¹ The trade-off is lower regain risk against staying on a medicine indefinitely; worth raising with your prescriber.

What we don't know

Who regains and who does not: SURMOUNT-4 reports group averages, not who sits where.¹ No trial has tested whether a step-down taper changes regain, or exercise begun at the point of stopping.⁵ Whether the quiet many call the end of "food noise" is a direct effect on reward signalling in the brain is still being researched. No trial has timed the return of appetite or the fading of gut symptoms after the last dose, or measured mood or energy after stopping tirzepatide.^{1, 12}

Frequently asked questions

How long does it take to feel normal after stopping Mounjaro?

Tirzepatide is largely cleared within about a month of your last injection: its level halves about every five days, so around 3% is left at day 25.² Appetite is expected to come back over that window as the level falls, but no trial has timed the fading of gut symptoms or the return of hunger day by day, so a precise number of days or weeks is not something the record gives.^{1, 12}

Can you stop Mounjaro cold turkey?

The NHS says not to stop suddenly, and to talk to your doctor, who may suggest reducing the dose gradually.³ The medicine leaves the body gradually whichever way you stop,² and no trial has tested whether a taper changes regain.⁵ Tell your prescriber before you stop.

Is there withdrawal from Mounjaro?

Not in the sense of physical dependence or a withdrawal syndrome. What people describe is the return of appetite and food noise as the body's own hunger hormones reassert themselves.

Is it possible to keep the weight off after stopping Mounjaro?

Yes, for some people, with deliberate, ongoing effort. Full regain is not universal: in SURMOUNT-4 the placebo group were still 9.9% below their starting weight a year after stopping, on average.¹ The hunger hormones behind regain stay altered for at least a year after weight loss,⁴ which is biology, not a personal failing.

Why do people stop taking Mounjaro?

Side effects, cost, supply gaps, reaching a goal weight, planning a pregnancy (the NHS advises stopping at least four weeks before trying),³ or a prescriber's decision. Whatever the reason, appetite returns on the same timetable.

Sources

1. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024. Randomised withdrawal trial (SURMOUNT-4), 670 adults, 52 weeks after a 36-week lead-in; registered outcome measures (ClinicalTrials.gov NCT04660643) from randomisation at week 36 to week 88: body weight, waist circumference, BMI, fasting glucose, HbA1c, fasting insulin, lipids, blood pressure and two physical-function questionnaires, no appetite or hunger measure; manufacturer-funded. PubMed 38078870.
2. Tirzepatide Summary of Product Characteristics, sections 4.6 (discontinue at least 1 month before a planned pregnancy because of the long half-life), 4.8 and 5.2 (maximum concentration 8 to 72 hours post dose; steady state after 4 weeks of once-weekly dosing; elimination half-life approximately 5 days), electronic medicines compendium, date of revision of the text 29 August 2026. medicines.org.uk.
3. NHS. Tirzepatide. Page last reviewed 15 May 2026. nhs.uk/medicines/tirzepatide.
4. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine, 2011. Prospective study, 50 adults, 62 weeks; funded by Australia's National Health and Medical Research Council. PubMed 22029981.
5. Zeigler Z, et al. Structured exercise during and after incretin-based pharmacotherapy discontinuation: a narrative review of mechanisms, evidence and prescription guidance. Healthcare, 2026. Narrative review; the exercise finding comes from one liraglutide trial; no conflicts declared. PubMed 42588312.
6. Flore G, et al. Weight maintenance after dietary weight loss: systematic review and meta-analysis on the effectiveness of behavioural intensive intervention. Nutrients, 2022. Pooled analysis of 8 trials, 1,454 adults, at least 12 months; no conflicts declared. PubMed 35334917.
7. Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025. Scan substudy of a randomised trial, 160 adults, 72 weeks; manufacturer-funded. PubMed 39996356.
8. Sardeli AV, et al. Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis. Nutrients, 2018. Pooled analysis of 6 randomised trials in older adults with obesity, 12 to 24 weeks; no conflicts declared. PubMed 29596307.
9. Leidy HJ, et al. The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition, 2015. Narrative review of meta-analyses and feeding trials; funding not stated on PubMed. PubMed 25926512.
10. NHS. How to get more fibre into your diet. Page last reviewed 2 March 2026. nhs.uk.
11. Xie W, et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Frontiers in Pharmacology, 2022. Pooled analysis of 37 randomised trials, 3,048 adults with type 2 diabetes; HbA1c 0.63 percentage points lower; no conflicts declared. PubMed 36467075.
12. Qi H, et al. Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis. PeerJ, 2026. Pooled analysis of five randomised trials and one single-arm study of semaglutide or tirzepatide, 8,993 adults, follow-up at least 48 weeks after stopping; gut adverse events fewer after stopping in the two trials reporting them (1,473 adults; moderate certainty), not timed; the weight outcomes rated low to very low certainty; funded by a Chinese pharmaceutical association research grant; no competing interests declared. PubMed 42729958.

Spotted something out of date? Email support@wellgard.co.uk with the page address and the sentence.

General information, not medical advice. Mounjaro is a prescription medicine: follow your prescriber's instructions and speak to your GP or prescriber before stopping or changing how you take it, particularly if you take it for type 2 diabetes.